Total product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) Jakafi® (ruxolitinib) revenues of $466 million in Q1 2021 (+1% vs Q1 2020); reaffirming full year guidance of $2.125-$2.20 billionPemazyre® (pemigatinib) now also approved in Europe and Japan, becoming the first internally discovered pro...